The contemporary discovery of extremely versatile engineered nucleic acid-binding proteins has transformed a brave new world in the genome-editing scientific area. Clustered regularly interspaced short palindromic repeats (CRISPR)-mediated programmable nucleic acid-binding proteins have brought about a revolution in diagnostic platforms. The groundbreaking finding that bacteria and archaea that harbored prokaryotes have transmitted adaptive immunity through CRISPR and CRISPR-associated (Cas) proteins has driven revolutionary advances in molecular biology. Importantly, advances in gene editing focus how expanding visions in CRISPR-Cas biology are revolutionizing the area of molecular diagnostics for identifying DNA and RNA in emerging microbiological pathogens, for single nucleotide polymorphism (SNP) identifications, and for cell-free mutation. Recent advances, such as improvements in multiplexing and quantitative capabilities as well as instrument-free detection of nucleic acids, will potentially leverage the introduction of these novel technologies to detecting bacteria and viruses at the point of care (POC). In this review, we highlight the fundamental features of CRISPR/Cas-based molecular diagnostic technologies and summarize a vision of the next applications for identifying pathogens in POC settings.

中文翻译：

---

使用基于 CRISPR 的可编程核酸结合蛋白进行床旁病原体检测

当代发现的极其通用的工程核酸结合蛋白已经改变了基因组编辑科学领域的一个勇敢的新世界。成簇的规则间隔短回文重复序列 (CRISPR) 介导的可编程核酸结合蛋白带来了诊断平台的革命。具有原核生物的细菌和古生菌通过 CRISPR 和 CRISPR 相关 (Cas) 蛋白传递适应性免疫这一突破性发现推动了分子生物学的革命性进步。重要的是，基因编辑的进展集中在 CRISPR-Cas 生物学的扩展视野如何彻底改变分子诊断领域，以识别新兴微生物病原体中的 DNA 和 RNA、单核苷酸多态性 (SNP) 鉴定和无细胞突变。最近的进展，例如多路复用和定量能力的改进以及核酸的无仪器检测，将有可能利用这些新技术的引入在护理点 (POC) 检测细菌和病毒。在这篇综述中，我们强调了基于 CRISPR/Cas 的分子诊断技术的基本特征，并总结了在 POC 环境中识别病原体的下一个应用的愿景。